期刊文献+

人心型脂肪酸结合蛋白(H-FABP)的原核表达、纯化和冻干品的制备

The Expression and Purification of Human Heart-type Fatty Acid Binding Protein and Preparation of Lyophilized Protein
原文传递
导出
摘要 目的:获得重组人心型脂肪酸结合蛋白,分析其活性及制备冻干品。方法:从GenBank中检索人源H-FABP CDs序列,合成基因后构建原核表达载体pET-28a(+)-H-FABP。将表达载体转入E.coli BL21(DE3),摸索pET-28a(+)-H-FABP最佳诱导条件,表达并纯化重组蛋白。使用检测试剂检测纯化后的重组H-FABP活性,研究最佳冻干方案并考察冻干品的稳定性。结果:经过优化诱导条件,重组H-FABP在BL21(DE3)中以可溶性蛋白形式表达。诱导条件为OD600≈0.6,IPTG终浓度0.4mmol/L,30℃诱导4h。通过Ni2+亲和层析纯化可得到纯度大于95%的重组HFABP蛋白。重组H-FABP冻干品可以在37℃稳定保存12d,25℃、4℃稳定保存至少4个月。结论:本项研究中的重组H-FABP表达体系成熟、蛋白活性高,冻干品稳定性好,为后续研究提供了稳定高效的生物原材料。 Objective: To obtain recombinant Human Heart-type Fatty Acid Binding Protein, detect its activity and prepare lyophilized protein. Methods: The CDs of Human H-FABP was searched from GenBank, synthesized into cloning vector, pET-28a ( + )-H-FABP was constructed and transformed into E. coli BI21 (DE3). After the optimal induction condition being researched, plenty of recombinant H-FABP was induced. Recombinant H-FABP was purified by Ni Sepharose 6 Fast Flow affinity chromatography and prepared into lyophilized protein. The activity of purified recombinant H-FABP and its lyophilized protein were detected by Wondfo H-FABP Test. Results : At the optimized induction condition ( OD600/0. 6, IPTG/0.4mmol/L, Induced for 4h at 30℃ ), recombinant H-FABP was expressed as soluble protein in E. coli BI21 (DE3). High activity recombinant H-FABP was obtained with over 95% purity by Ni-chelating affinity chromatography. Lyophilized protein of recombinant H-FABP was stable for 12 days at 37℃ and 4 or more months at 25℃. Conclusion: The expression system established in this research is feasible and efficient. Lyophilized protein is stable enough to be provided as biological raw materials for further research.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2014年第3期79-83,共5页 China Biotechnology
关键词 心型脂肪酸结合蛋白 原核表达 冻干品 急性心肌梗死 Heart fatty acid binding protein Prokaryotic expression Lyophilized protein Acute myocardial infarction
  • 相关文献

参考文献11

  • 1戚文航. 急性心肌梗死的流行病学及治疗进展. 现在实用医学, 2009, 16(111): 632-634.
  • 2Wu H B, Panteghini M, Apple F, et al.Biochemical markers of cardiac damage: From traditional enzymes to cardiac-specific proteins.Scandinavian Journal of Clinical & Laboratory Investigation, 1999, 59(230):74-82.
  • 3潘柏申.心脏标志物检测标准化研究进展[J].中华检验医学杂志,2007,30(4):467-471. 被引量:7
  • 4Glatz J F, Vusse G J, Simoons M L, et al.Fatty acid-binding protein and the early detection of acute myocardial infarction.Clin Chim Acta, 1998, 272(1):87-92.
  • 5Appie H, Kleine F, Glatz C, et al.Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man.Molecular and Cellular Biochemistry, 1992, 8(116):155-162.
  • 6Nakata T, Hashimoto A, Hase M, et al.Human Heart-Type Fatty Acid-Binding Protein as an Early Diagnostic and Prognostic Marker in Acute Coronary Syndrome. Cardiology, 2003, 99(2):96-104.
  • 7Junnichi I, Wang J H, Hiroyuki N, et al.Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction.Clinical Chemistry, 1997, 43(8): 1372-1378.
  • 8Glatz J F, Vusse G J.Cellular fatty acid-binding protein: current concepts and future directions. Mol Cell Biochem, 1990, 6(89):237-251.
  • 9Chmurzynska A.The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism.Journal of Applied Genetics, 2006, 47(1):39-48.
  • 10Schaap G, Spechtb Bernfried, Vussea J, et al.One-step purification of rat heart-type fatty acid-binding protein expressed in Escherichia coli.Journal of Chromatography B: Biomedical Sciences and Applications, 1996, 679(1-2): 61-67.

二级参考文献28

  • 1钱应璞.制剂药品的冻结真空干燥技术[J].机电信息,2004(15):3-11. 被引量:8
  • 2潘柏申,张万忠,陈铭生,郭玮,周华文,倪星忠.上海地区血清丙氨酸转氨酶测定结果一致性和参考范围调查[J].检验医学,2005,20(5):417-420. 被引量:11
  • 3Panteghinia M, Linsingerb T, Wu AHB, et al. Standardization of immunoassays for measurement of myoglobin in serum. Phase I:Evaluation of candidate secondary reference materials. Clin Chim Acta,2004,341:65-72.
  • 4Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem, 2005,51:486-493.
  • 5Armani A, Becker RC. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part I. Am Heart J,2005,149:971-976.
  • 6Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessment. Clin Chem ,2003,49 : 1258-1271.
  • 7Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four automated high-sensitivity C-reactive protein methods:implications for clinical and epidemiological applications. Clin Chem ,2000,46 :461-468.
  • 8The Joint European Society of Cardiology/American College Cardiology Committee. Myocardial infarction redefined :a consensus document of the Joint European Society of Cardiology/American College Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardial,2000,36:959-969.
  • 9Jaffe AS,Ravkilde J,Roberts R,et al. It's time for a change to a troponin standard. Circulation ,2000,102 : 1216-1220.
  • 10Datta P,Foster K,Dasgupta A. Comparison of immunoreactivity of five human cardiac troponin I assay toward free and complexed forms of the antigen: implications for assay discordance. Clin Chem, 1999,45:2266-2269.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部